ProVee demonstrates sustained LUTS improvement with preserved sexual function

In this video Steven A. Kaplan, MD, director of the Men's Wellness Program at Mount Sinai Health System and a professor at Icahn School of Medicine at Mount Sinai, discusses his expectations for the long-term durability of the ProVee System and its potential to fundamentally shift the treatment paradigm for men with lower urinary tract symptoms due to benign prostatic hyperplasia.

Based on 12-month data showing sustained improvements in International Prostate Symptom Score, Kaplan expresses confidence that symptom relief will extend to 2 and 3 years and beyond. A key reassuring signal, in his view, is the low rate of device removals, which were not driven by recurrent symptoms. He notes that if significant late issues were emerging, widespread removals would already be occurring. Even in a hypothetical scenario where durability lasts 3 to 5 years before removals are needed, Kaplan emphasizes that the device’s minimally invasive and repeatable nature makes replacement or transition to another therapy entirely reasonable.

Kaplan frames the greatest value of ProVee not as competition with other procedures, but as a compelling alternative to chronic medical therapy. He is particularly critical of the widespread polypharmacy often required to manage a quality-of-life condition, citing patients on combinations of alpha blockers, 5-alpha reductase inhibitors, PDE5 inhibitors, and bladder agents. He argues that long-term medication use for urinary symptoms is disproportionate, especially in older patients already managing multiple drugs. From this perspective, even a few years of durable symptom relief without pills represents a major advance. Kaplan highlights ProVee’s ease of use, reversibility, and ability to shift care away from lifelong medications.

Regarding sexual function, Kaplan underscores the absence of sustained retrograde ejaculation or erectile dysfunction in the trial. He attributes this preservation to precise device placement, which avoids critical anatomical structures such as the verumontanum and sphincter mechanism. By remaining proximal to these “business mechanisms,” ProVee minimizes risk to sexual and urinary function. Kaplan expresses strong confidence that urologists can offer the procedure to sexually active men prioritizing functional outcomes, emphasizing its technical simplicity and reproducibility.